How Compounded GLP-1 Prices Moved Over the Last 16 Months: Provider-by-Provider Trajectories

Weight Loss Rankings has tracked monthly cash prices for compounded semaglutide across the largest US telehealth providers since January 2025. As of April 2026, our dataset contains 96 monthly observations across 6 providers spanning roughly 15 months. Every single provider in the tracked set has cut its monthly cash price since January 2025 — by an average of 25%. But the rate at which they cut tells a much more interesting story than the average.

The full trajectory: every tracked provider, sorted by % cut

Here's the price each provider was charging at the start of our tracking period, what they're charging in the most recent monthly snapshot, and the percentage change between the two. Sorted by biggest cutter first.

The biggest cutter and the smallest

Hims cut its compounded semaglutide price by 43% over the tracking period — from $349 per month at the start to $199 as of April 2026. That's a real-dollar cut of $150 per month, or roughly $1,800 per year for a patient on the same provider for 12 months.

At the other end, CoreAge Rx moved the least — only 13% off its starting price of $229. The explanation isn't that CoreAge Rx is unusually expensive today; it's that CoreAge Rx was already cheap at the start of the tracking period. Providers that started near the eventual market floor had less room to fall.

The convergence: every provider is heading for the same floor

Looking at the most recent month in isolation, the spread between the most expensive and the cheapest provider in the tracked set is just $30 — from $199 to $229. Compare that to the spread at the start of the tracking period, which was much wider. What you're looking at is a market converging on a structural floor around $199.

That convergence is the most editorially significant pattern in the data. Compounded semaglutide doesn't have a regulated cost basis the way brand-name Wegovy does — every provider is free to set whatever price the market will bear, and the wholesale active pharmaceutical ingredient cost is roughly the same for everyone. The fact that the spread has narrowed dramatically over our tracking window is what economists call price convergence under perfect information: as patients comparison-shop and competitors cross-reference each other, the market discovers a floor price and the high-margin outliers are forced down to it.

The structural floor over time

Plotting the minimum monthly cash price across our multi-point tracked set at four snapshot dates — the start of tracking, mid-2025, the end of 2025, and the latest refresh — shows the floor's descent and where it stabilized.

Why prices have moved (and what comes next)

Three forces have driven the cuts visible in the table above:

1. Wholesale API costs. The active pharmaceutical ingredient (semaglutide base) is sourced by 503A and 503B pharmacies from FDA-registered API manufacturers. Wholesale API pricing has fallen meaningfully since 2024 as more API manufacturers entered the market. Lower input costs let compounders cut retail prices without giving up margin.
2. Comparison shopping. Sites like our live price tracker, plus provider review aggregators, made it trivial for patients to compare prices across providers. When the cheapest provider is one click away, charging 50% above the floor isn't a sustainable strategy. Our cheapest compounded semaglutide investigation documents the floor-price providers we've verified at any given snapshot.
3. FDA enforcement risk. Multiple GLP-1 telehealth providers received FDA warning letters for marketing language, labeling violations, and salt-form sourcing — see our FDA warning letter investigation for the full pattern. Every enforcement action shrinks the potential customer base of the cited provider, increasing competitive pressure on the survivors and forcing prices down further. The PCAB accreditation investigation breaks down which fulfillment pharmacies actually meet the higher quality bar.

Looking forward: based on the convergence pattern, we expect the spread between the most expensive and cheapest tracked provider to narrow further over the next 6 months, with the floor staying near $199 unless wholesale API prices change materially. Providers still charging meaningfully above the floor — see the bottom of the table above — are the ones most likely to announce cuts in upcoming pricing updates. We'll surface those changes in our live pricing index as the data comes in.

Why this article updates automatically

Every number above is computed at render time from our editorial price-history dataset. When the next monthly snapshot lands — the scraper writes a new data point on the first of each month for every provider in the tracked set — the trajectories, the biggest-cutter / smallest-cutter callouts, and the convergence spread all recompute automatically. If a new provider enters our long-term tracked set (after enough months of consistent data), they get added to the table without an editor having to touch anything. If an existing provider raises prices, the table will show that too.

Last data refresh: April 2026. Methodology and sources are documented at our editorial methodology page. The full pricing dataset across all 80+ providers we track — including providers without enough history yet for a multi-month trajectory — is available on the live price tracker.